6c Price Target - BUY - Research report just out, page-15

Chuckm61-Do you really do any research?

Photosoft efficiently destroys ovarian cancer cells in vitroPosted on July 5, 2018 by Company SecretaryInvion and Hudson Institute of Medical Research are collaborating on R&D projects for the PhotosoftTM technology as a treatment of a range of cancersPhotosoftTM characterisation studies have been completed in multiple ovarian cancer cell linesPhotosoftTM caused efficient and highly effective cancer cell destruction in vitroMelbourne, Australia, 5 July 2018: Invion Limited (ASX: IVX, “Invion” or “Company”) is pleased to announce that initial characterisation of the novel chlorophyll based photodynamic therapy, PhotosoftTM in ovarian cancer has been completed under its Research & Development Alliance Agreement with leading Australian medical research institute, Hudson Institute of Medical Research (“Hudson Institute”).Spectral characteristics, cellular uptake and clearance, intracellular localisation, dark and photo-toxicity were investigated in multiple ovarian cancer cell lines (human and murine) in both 2D and 3D organoid culture in vitro. PhotosoftTM caused efficient and highly effective cancer cell destruction in vitro, with 100% cell death achieved in a matter of minutes following light activation.In the absence of light activation, PhotosoftTM was completely non-toxic to cells – highlighting its potential for clinical application without inducing non-specific phototoxicity, a major impediment experienced in the clinical application of other photosensitiser compounds.Photodynamic Therapy (PDT), combining a photo-sensitising compound and light to generate destructive reactive oxygen species, is an effective strategy for tumour tissue ablation. The efficiency of a photosensitiser is one of the main factors for determining its feasibility as a Photodynamic Therapy. Whilst several photosensitisers are clinically approved, some have undesirable properties including extreme photosensitivity, poor water solubility and inadequate selectivity, limiting their clinical application.Dr Andrew Stephens, Group Head of the Ovarian Cancer Biomarkers Research Group at Hudson Institute said, “The Photosoft characterisation studies demonstrate that PhotosoftTM efficiently produces reactive oxygen species to destroy tumour cells in vitro, and that modulation of light energy can be used to control the mechanism of induced cell death.”Managing Director and Chief Executive Officer, Dr Greg Collier, said “Ovarian cancers have a greater than 70% 5-year mortality rate, and patients almost universally develop recurrent, chemo-resistant disease. New therapies are urgently needed and we are very pleased with this early progress under our R&D Alliance Agreement with Hudson Institute. This data lays the groundwork for ongoing preclinical trials of the PhotosoftTM technology as an indication for chemo-resistant, solid ovarian tumours.”Further results of these studies will be presented in September 2018 at a major international conference.